An observational study in Metastatic Breast Cancer, Advanced Breast Cancer and Estrogen Receptor-positive Breast Cancer, sponsored by Rush University Medical Center. Completed. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-03-31.
Sponsored by Rush University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if patients with ER+, human epidermal growth factor 2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring based on manufacturer recommendations at a tertiary academic medical center.
This study was a retrospective, single-center study that included women receiving palbociclib for the treatment of ER+, HER2- advanced breast cancer. Exclusion criteria were the presence of brain metastases or active enrollment in a palbociclib clinical trial.
The primary endpoint was the proportion of patients who were maintained on a palbociclib dose according to the adjustment schedule in package insert recommendations.
The secondary endpoints were the number of patients dose adjusted for hematologic toxicities, the number of patients experiencing neutropenia, duration of therapy, progression-free survival (PFS), and adherence to manufacturer monitoring recommendations.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 67 is below the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Rush University Medical Center is the lead sponsor of 397 studies on the registry; 61 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
All patients seen at RUMC
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
Drug: Palbociclib
Observe patients receiving palbociclib for dose adjustment and lab monitoring
Also known as: IBRANCE
Palbociclib dose according to the package insert recommendations.
Identify the proportion of patients who were maintained on a palbociclib dose according to the package insert recommendations.
Time frame: 22 months
Dose adjustment for hematologic toxicities
Number of patients who required dose adjustment for hematologic toxicities while on the study.
Time frame: 22 months
Number of patients who experienced neutropenia.
Patients who experienced neutropenia as a result of their participation in the study.
Time frame: 22 months
Duration of therapy
Number of patients who completed the study compared to the number of patients who were was discontinued with the most common reason for discontinuation being disease progression
Time frame: 22 months
Progression free survival (PFS)
Progression free survival duration of patients that were in the study who received Palbociclib
Time frame: 22 months
Adherence to manufacturer monitoring recommendations
Patient adherence was also a limitation of this study as providers relied on the patient report to track medication adherence. Insurance coverage and access to palbociclib also contributed some variability as there were occasional delays in initiation of therapy or change in dose.
Time frame: 22 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2015 to primary completion in Dec 2016, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center →